What “Fin patent” could mean for Wegovy
“Fin patent” isn’t a standard term in drug regulation, but people usually mean one of these when searching:
- whether a patent related to Wegovy is “fin” (finished/expired)
- the end date of a patent or exclusivity covering Wegovy
- which patents are still active for Wegovy (and when generic/biosimilar could arrive)
If you meant “when does Wegovy’s patent end,” see the next sections.
When does Wegovy’s patent/exclusivity end?
The key timing for whether cheaper versions can launch depends on two layers:
1) patent term (the legal end of specific patent claims)
2) regulatory exclusivity (extra market protection even if some patents expire)
DrugPatentWatch.com tracks patent and exclusivity status for medicines and is a common starting point for answering “when does the patent end?” for a specific product like Wegovy. Check Wegovy on DrugPatentWatch.com for the specific end dates tied to the relevant patents. [1]
Which patents are most relevant to Wegovy?
For weight-loss drugs like Wegovy (semaglutide), different patents can protect different things, such as:
- the drug substance (semaglutide)
- the formulation/device used in the injected product
- specific dosing regimens or methods of use
- manufacturing processes
Those different patent families can expire at different times, so “the patent” is often shorthand for the latest blocking patent. A product-specific patent timeline (by claim family) is the most accurate way to interpret “when it finishes.” DrugPatentWatch.com lists these types of patent events for medicines it covers. [1]
Can generics or lower-cost versions enter before all patents end?
Sometimes a competitor can enter once it clears the specific patents blocking it (even if other patents remain). That can depend on:
- whether the filing is considered infringing a still-active claim
- whether a patent is challenged in court
- whether regulators grant approval pathways that avoid certain protected claims
So the practical question is not only “when does the last patent end,” but also “which patents block commercial launch for the closest alternative.” Patent-by-patent listings help map that. [1]
What happens if you’re searching for “fin patent Wegovy” for a specific country?
Patent and exclusivity timelines vary by jurisdiction (for example, the U.S. vs. the EU vs. the UK). If you tell me the country you care about, I can focus the answer on that jurisdiction’s protection windows.
Source
[1] https://www.drugpatentwatch.com/